Stockscreener 앱 받기
3.43
2.83%
-0.10
시간 외 거래:
3.41
-0.02
-0.58%
Mannkind Corp 주식(MNKD)의 최신 뉴스
FDA approves MannKind’s Afrezza inhaled insulin for children with diabetes - Investing.com
FDA clears MannKind (NASDAQ: MNKD) Afrezza use in children 6 and older - Stock Titan
MannKind Corp stock (US5638651064): Afrezza pediatric FDA approval and share price weakness draw foc - AD HOC NEWS
MNKD stock eyes best month since 2022 ahead of FDA decision on pediatric diabetes treatment - MSN
symbol__ Stock Quote Price and Forecast - CNN
MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market - Yahoo Finance
MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children - Stocktwits
FDA approves Afrezza for children and adolescents with diabetes - Managed Healthcare Executive
US FDA approves MannKind's inhaled insulin for children - Reuters
MannKind Corporation (MNKD) Receives FDA Approval for Pediatric Use of Afrezza - GuruFocus
MannKind (MNKD) Receives FDA Nod for Pediatric Use of Afrezza - GuruFocus
Inhaled insulin for kids: MannKind hosts call on new Afrezza use - Stock Titan
MannKind wins FDA approval for inhaled insulin for children with type 1, type 2 diabetes - MassDevice
US FDA approves MannKind’s inhaled insulin for children By Reuters - Investing.com
MannKind’s Afrezza approved for children with diabetes - Investing.com
MannKind Corporation Announces FDA Approval of Afrezza® Inhalation Powder for Pediatric Use in Type 1 and Type 2 Diabetes - Quiver Quantitative
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes - The Manila Times
FDA approves first inhaled mealtime insulin for kids 6+ - Stock Titan
MNKD Technical Analysis | Trend, Signals & Chart Patterns | MANNKIND CORP (NASDAQ:MNKD) - ChartMill
MannKind Corporation Files Form 8-K Announcing Regulatory Update and Company Information (May 27, 2026) - Minichart
FDA drops MannKind (NASDAQ: MNKD) Afrezza pulmonary malignancy trial demand - Stock Titan
MNKD Stock Eyes Best Month Since 2022 Ahead Of FDA Decision On Pediatric Diabetes Treatment - Yahoo Finance
MNKD Stock Heads For Strongest Month In Over Three Years As FDA Catalyst Draws Closer - Stocktwits
Top Companies in Diabetes Drug Therapy MarketAbbott - openPR.com
MannKind to Present at Jefferies Global Healthcare Conference - Yahoo Finance
New data on inhaled insulin for kids as FDA weighs Afrezza - Stock Titan
MannKind Corporation 8-K Filing Details Board Election Results and Company Information (May 2026) - Minichart
Director Michael A. Friedman awarded 82,781 MannKind (MNKD) restricted stock units - Stock Titan
MannKind director (MNKD) awarded stock and RSUs, updates holdings - Stock Titan
MannKind (MNKD) director Jennifer Grancio granted 82,781 restricted stock units - Stock Titan
Director Sabrina Kay (NASDAQ: MNKD) awarded 82,781 MannKind RSUs - Stock Titan
MannKind shareholders elect directors and approve proposals at annual meeting - Investing.com
MannKind (NASDAQ: MNKD) reports 2026 annual meeting voting results - Stock Titan
MannKind (MNKD) HR chief adds 33,898 shares under stock purchase plan - Stock Titan
MNKD stock records biggest single-day gains in over 5 years, breaches a key technical milestone – what’s driving this rally? - MSN
MannKind Corp stock (US5638651064): inhaled insulin specialist draws attention after recent business - AD HOC NEWS
MannKind Corp stock (US5638651064): focus on Afrezza growth and partnership pipeline - AD HOC NEWS
FY2026 EPS Estimates for MannKind Increased by HC Wainwright - MarketBeat
MannKind Corp. (MNKD) Reports Q1 2026 Total Revenues of $90.2M - Insider Monkey
MannKind Corp stock (US5638651064): respiratory drug specialist in focus after latest quarterly upda - AD HOC NEWS
5 Best NASDAQ Stocks Under $5 to Buy Right Now - Insider Monkey
MNKD (NASDAQ) amendment shows RSU resale filing via Morgan Stanley - Stock Titan
MannKind Corp stock (US5638651064): Biopharma innovator in inhaled therapies - AD HOC NEWS
Mannkind director Steven Binder sells $55,732 MNKD stock - Investing.com
MannKind EVP David Thomson sells $9,978 in company stock By Investing.com - Investing.com India
MannKind EVP David Thomson sells $9,978 in company stock - Investing.com India
Mannkind director Steven Binder sells $55,732 MNKD stock By Investing.com - Investing.com Nigeria
MANNKIND CORP (MNKD) officer has shares withheld to cover RSU taxes - Stock Titan
MannKind (MNKD) EVP trades shares under pre-set Rule 10b5-1 plan - Stock Titan
2.89%
자본화:
|
볼륨(24시간):